Source comparison
Is Ipamorelin Legal: Regulatory Comparison
Understanding where ipamorelin fits within the broader regulatory landscape requires comparison with related compounds. The table below maps regulatory status, sourcing legality, and enforcement risk across growth hormone secretagogues and related peptides. Ip
This comparison does not assign a generated winner or score.
- Understanding where ipamorelin fits within the broader regulatory landscape requires comparison with related compounds. The table below maps regulatory status, sourcing legality, and enforcement risk across growth hormone secretagogues and related peptides.
- Ipamorelin
- IND (investigational). Not approved
- Yes, with research-use-only labeling
- No, except within IRB-approved trials
- Therapeutic marketing claims
- Third-party purity verification + proper labeling + GMP standards
- Sermorelin
- Direct-to-consumer marketing
- Same as ipamorelin
- CJC-1295
- Online pharmacy sales without prescription
- BPC-157
- No, under any circumstance outside trials
- Injury recovery claims
- Tesamorelin
- FDA-approved (Egrifta) for HIV-associated lipodystrophy
- Yes, separate research-grade sourcing
- Yes, via prescription for approved indication only
- Off-label prescribing for non-approved uses
- Research-grade must be labeled separately from pharmaceutical-grade
- Semaglutide
- FDA-approved (Ozempic, Wegovy) for diabetes and obesity
- Yes, via prescription for approved indications
- Compounding without FDA approval
- Research-grade must not be marketed as therapeutic
- The table reveals a critical pattern: ipamorelin legal status mirrors that of other investigational peptides. Fully permissible for research, fully prohibited for human therapeutic use outside of clinical trials. The distinction between ipamorelin and FDA-approved peptides like tesamorelin is not molecular safety but evidentiary completeness. Tesamorelin completed Phase III trials demonstrating efficacy and safety for a specific indication, while ipamorelin remains in preclinical and early-phase investigation. This doesn't mean ipamorelin is unsafe; it means the FDA has not reviewed sufficient clinical data to authorize marketing for any human therapeutic purpose.